CUMULATIVE YEAR-END INDEX—1999
SMALL ANIMAL/EXOTICS AUTHOR INDEX

A

Allen, S. W., 524
Anderson, M. A., 601, 861
Andrew, S. E., 1064

B

Bagley, R. S., 1158
Behrend, E. N., 235
Bellows, J., *Perioceutic Roundtable* (February supplement)
Bennett, R. A., 815, 1049
Benson, K. G., 50, 116
Blagburn, B. L., *Clinical Advances* (September supplement)
Boeckh, A., 66, 905, *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Boothe, D. M., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Boothe, H. W., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Bovée, K. C., *1998 Purina Nutrition Forum Proc* (November supplement)
Brooks, D. E., 1064
Brown, S. A., 752, *1998 Purina Nutrition Forum Proc* (November supplement)
Buzhardt, L. F., *Clinical Advances* (September supplement)

C

Cambridge, A. J., 1158
Campbell, K. L., 299
Camps-Palau, M. A., 587
Chabanne, L., 155, 402
Chalmers, W. S. K., *Clinical Advances* (October supplement)
Charuvastra, E., 1025
Chew, D. J., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Chisholm-Chait, A., 158, 218
Chun, R., 622
Cleland, P., *Perioceutic Roundtable* (February supplement)
Coates, J. R., 440
Coleman, E. S., 641
Colley, P., 44
Colmery, B., *Perioceutic Roundtable* (February supplement)
Connors, R. L., 1158
Converse-Peters, L. J., *Oxygen Carrying Fluids* (August supplement)
Cornick, J. L., 587
Côté, E., 1025
Crystal, M. A., *Oxygen Carrying Fluids* (August supplement)

D

Davidson, G., 494, 1118
Dawson, S., *Clinical Advances* (October supplement)
Day, T. K., *Oxygen Carrying Fluids* (August supplement)
Deem, S. L., 205, 529
DeManuelle, T. C., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Dewey, C. W., 440, 922, 1037
Dhaliwal, R. S., 1059
Dhupa, N., 1014, 1124
Dillon, R., *Clinical Advances* (September supplement)
Drobatz, K., 397
Dryden, M. W., 296
Dubey, J. P., 347
Ducoté, J. M., 440, 638
Duncan, K., *Clinical Advances* (October supplement)
Dupont, G. A., *Perioceutic Roundtable* (February supplement)
Duran, S. H., 424

E

Ellison, G. W., 580
Emily, P., *Perioceutic Roundtable* (February supplement)

F

Fahey Jr., G. C., *1998 Purina Nutrition Forum Proc* (November supplement)
Finco, D. R., *1998 Purina Nutrition Forum Proc* (November supplement)
FitzSimons, H., 524
Flammer, K., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Forrester, S. D., 910
Fortney, B., *Clinical Advances* (October supplement)
Fournel, C., 155, 402
Fox, P. R., 478
Freeman, L. M., 512

G

Garrod, L. A., 800
Gaynor, A. R., 1014, 1124
Göbel, T., *1999 NAVC Antimicrobial Therapy Exotics Proc* (March supplement), *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Goggin, J. M., *1998 Purina Nutrition Forum Proc* (November supplement)
Graham, J. C., 299
Greenacre, C. B., 581, 524, 633
Grubb, T., 428, 843
Gugisberg, G., *Clinical Advances* (October supplement)

H

Hamilton, H. L., 946
Hannah, S. S., *1998 Purina Nutrition Forum Proc* (November supplement)
Harrington, M. L., 1158
Harris, D. J., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Hathcock, T. L., 954
Hawkins, B. J., 98, *Veterinary Exchange* (January supplement), *Perioceutic Roundtable* (February supplement)
Hazewinkel, H. A. W., *1998 Purina Nutrition Forum Proc* (November supplement)
Heinen, E., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Henderson, R., 44
Horeish, C., 1118
Hoskins, J. D., *Clinical Advances* (October supplement)
Howe, L. M., 103, 197
Huber, M., 44

I

Ihrke, P. J., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Isaacs, J. P., 246

J

Jacobs, A. A. C., *Clinical Advances* (October supplement)
Jacobson, E. R., *1999 NAVC Antimicrobial Therapy Exotics Proc* (March supplement)
James, K., *1998 Purina Nutrition Forum Proc* (November supplement)
Jerram, R. M., 922, 1037
Johnston, D. E., 414

K

Kalkstein, T. S., 15, 148, 387, 497
Kallberg, M. E., 1064
Kealy, R. D., *1998 Purina Nutrition Forum Proc* (November supplement)
Kennis, R. A., 1108
Kietzmann, M., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
King, L. G., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Kitchell, B. E., 1059
Komaromy, A. M., 1064
Kruger, J. M., 15, 148, 387, 497

L

Landsberg, G. M., 688
Lappin, M., *Clinical Advances* (October supplement)
Latimer, K. S., 633
Licari, L. G., *Oxygen Carrying Fluids* (August supplement)
Lindsay, D. S., 347
Lobprise, H. B., *Perioceutic Roundtable* (February supplement)
Lyon, K. F., *Perioceutic Roundtable* (February supplement)

M

MacDonald, J. M., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
MacEwen, E. G., 902
Manfra-Marretta, S., *Veterinary Exchange* (January supplement)
Marcellin-Little, D. J., 481
Martin, S., 145
McAllister, M., 347
McDonough, P., *Clinical Advances* (October supplement)
McLaughlin, S. A., 946
McMurray, D. N., *1998 Purina Nutrition Forum Proc* (November supplement)
Mensack, S., 541
Monestier, M., 155
Mongil, C. M., 414
Monier, J. C., 155, 402
Moore, M. P., 1158
Mott, J., *Oxygen Carrying Fluids* (August supplement)
Muir III, W. W., 428, 843
Murray, M. J., 194
Murtaugh, R., 541

N

Nap, R. C., *1998 Purina Nutrition Forum Proc* (November supplement)
Nielsen, D., *Veterinary Exchange* (January supplement), *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Norsworthy, G. D., *Clinical Advances* (October supplement)

O

Orosz, S. E., 935

SMALL ANIMAL/EXOTICS AUTHOR INDEX—(continued)

Osborne, C. A., 15, 148, 387, 497, *1998 Purina Nutrition Forum Proc* (November supplement)

P

Papich, M. G., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Pasman, J., *Clinical Advances* (October supplement)
Patil, A. R., *1998 Purina Nutrition Forum Proc* (November supplement)
Paul-Murphy, J., 30, 116
Peters, J. C., *Clinical Advances* (October supplement)
Phillips, B. S., 540
Pirro, F., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Polzin, D. J., *1998 Purina Nutrition Forum Proc* (November supplement), *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Power, H., *Clinical Advances* (September supplement)

R

Ramer, J. C., 30, 116
Ramsey, C. C., 1064
Ramsey, D. T., 1064
Rayne, E. M., *Clinical Advances* (October supplement)
Rees, C. A., 55
Remillard, R. L., 699
Richards, J., *Clinical Advances* (October supplement)
Richter, K., 1025
Rigal, D., 135, 402
Ritchie, B. W., 381, 524, 633, 694
Robertson, T. A., 128
Rosenthal, K. L., *1999 NAVC Antimicrobial Therapy Exotics Proc* (March supplement)
Roy, A. F., *Clinical Advances* (October supplement)

S

Saidla, J. E., *Veterinary Exchange* (January supplement)
Sartin, E. A., 954
Schmeer, N., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Shahar, R., 414
Shamir, M. H., 414
Silver, G. M., 1138
Sonsthagen, T., 796
Spano, J. S., 954
Steward, D., *Y2K for DVMs* (August supplement)
Stewart, A., *Y2K for DVMs* (August supplement)
Swaim, S. F., 946

T

Thomas, C. A., *Clinical Advances* (September supplement)
Threlfall, W. R., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Troy, G. C., 910

V

van Vugt, F., *Clinical Advances* (October supplement)
Visser, C. J., *Perioceutic Roundtable* (February supplement)

W

Wall, R. E., *Oxygen Carrying Fluids* (August supplement)
West, L., *Y2K for DVMs* (August supplement)
Wetmore, L., 800
Wheeler, J., 815, 1049
White, G., *Oxygen Carrying Fluids* (August supplement)
White, P. D., 716
Whitley, R. D., 946
Wiggs, R. B., *Perioceutic Roundtable* (February supplement)
Wilkie, S., *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
Williams, J., *Clinical Advances* (October supplement)
Wolf, A. M., 1108

Z

Zerbe, C. A., 1134
Zoran, D. L., 731, 824
Zsombor-Murray, E., 512

VOLUME 21 SMALL ANIMAL PAGINATION

Issue	*Pages*	*Issue*	*Pages*
January	**1–67**	**July**	**569–653**
February	**89–167**	**August**	**673–765**
March	**185–252**	**September**	**785–865**
April	**281–351**	**October**	**889–961**
May	**369–448**	**November**	**993–1077**
June	**465–547**	**December**	**1097–1146**

SMALL ANIMAL/EXOTICS SUBJECT INDEX

A

American Association of Feline Practitioners/Academy of Feline Medicine panel report (see Feline senior health care)
Anesthetic agents, for trauma patients, 800–811
  induction, 804–809
  maintenance, 809
  premedication, 802–804
  requirements, 800–802
Antimicrobial therapy, *1999 NAVC Antimicrobial Therapy Exotics Proc* (March supplement)
  avian bacterial infections and treatment, *I21–I32*
  bacterial diseases and therapy in small mammals, *I5–I20*
  in reptiles, *I33–I48*
Avians (see Respiratory system)

B

Behavior counseling, 688–690, 783
Blepharoplasty techniques, 946–953
  closure, 947–948
  equipment, 947
  neoplasia, 949
  patient preparation, 946–947
  postoperative care, 952
  repair, 949–952
  trauma, 948–949
Bone deformities (see External skeletal fixation)
Bordetella bronchiseptica, feline, *Clinical Advances* (October supplement)
  bordetellosis, *I6–I7*
  epidemiology, *I17–I18*
  infections, *I4–I5*, *I18*
  isolation and characterization, *I14–I16*
  research data, *I19–I20*
  roundtable discussion, *I22–I28*
  seroprevalence and isolation rate, *I17*
  transmission, *I17*
  vaccine studies, *I8–I13*

C

Cardiology, 478–479, 491
Carprofen, 246–248
Cartilaginous hyperplasia, in ball pythons, 633–637, 652
Chondroprotective agents, oral, 601–609, 861–865
  combination therapy, 605
  glucosamine hydrochloride/chondroitin sulfate/manganese ascorbate, 603–604
  glycosaminoglycan sources, 862–863
  labeling, 861–862
  nomenclature, 603
  S-adenosylmethionine, 604–605
  superoxide dismutase, 605
  synovial joint structure, 601–602
Cisapride, 324–326
Colonic disease
  canine, 824–841
    causes of constipation, 838–839
    causes of diarrhea, 826–838

SMALL ANIMAL/EXOTICS SUBJECT INDEX—(continued)

physiology, 824–826
feline, 731–748
causes of large bowel diarrhea, 732–747
physiology, 731–732
Controversies, veterinary, 1104–1105
Cyclophosphamide, 1059–1063

D

Dentistry (see also Microbes; Periodontal disease), 98–99, 112
Diabetes, canine, nutritional management of, 699–713
key factors, 700–708
patient assessment, 700
reassessment, 708–710
Diagnostic testing (see Hyperadrenocorticism)

E

Ethylene glycol, acute, intoxication, 1014–1023, 1124–1133
clinical stages, 1016–1018
clinicopathologic findings, 1018–1019
diagnosis, 1124–1126
metabolism and pathophysiology, 1015–1016
prevention, 1131
prognosis, 1131
treatment, 1126–1131
Etodolac, 494–495
Emergency and critical care medicine, 397–400
Emerging Technology (see Telemedicine)
Enalapril maleate, 1118–1121, 1176
Endectocide, topical, *Clinical Advances* (September supplement)
heartworm disease, *I*36–*I*40
parasite control, *I*46–*I*52
sarcoptic mange, canine, *I*41–*I*45
selemectin, *I*2–*I*35
Exotic animal medicine, 194–195, 266
Exotics Rounds (see Cartilaginous hyperplasia; Nutritional products; Toxicosis; Urinary bladder eversion)
External skeletal fixation, 481–491
complications, 489
diagnosis and treatment planning, 482–484
Ilizarov method, 484–486
postoperative care and deformity correction, 486–489

F

Famotidine, 424–425
Feline senior health care, 531–539, 612–621
anesthesia, 613–614
behavior problems, 537–538
feeding, 617
health care program, 532–534
nutrition, 614–617
oral cavity disease, 617–620
pain management, 612–613
pet loss, euthanasia, and grief, 620–621
selected considerations, 534–537
Ferrets, abdominal surgical procedures, 815–822, 1049–1057
adrenal diseases, 815–818
cystotomy, 1052–1054
gastrointestinal foreign bodies, 1049–1050
liver biopsy, 1051–1052
ovariohysterectomy, 1054–1057
pancreatic beta-cell tumors, 818–821
paraurethral or prostatic cysts, 818
splenomegaly, 1051
Flea control, 296–297, 327
Fluoroquinolones, *3rd Int Vet Symp on Fluoroquinolones Proc* (December supplement)
dermatology
comparison of enrofloxacin skin concentrations, *I*50–*I*56
pyoderma, German shepherd, *I*44–*I*49
use of systemic antimicrobials in canine bacterial otitis, *I*57–*I*59
periodontal disease
clinical experience with an enrofloxacin-metronidazole combination, *I*88–*I*94
pharmacology and microbiology
antimicrobial movement into tissues, *I*26–*I*31
bactericidal and inhibitory activity, *I*19–*I*25
comparative pharmacokinetics of enrofloxacin and difloxacin, *I*12–*I*18
pharmacokinetic properties, *I*7–*I*11
serum and tissue concentrations of enrofloxacin in dogs, *I*32–*I*39
time course of enrofloxacin and its active metabolite in peripheral leukocytes of dogs, *I*40–*I*45
respiratory tract infections
management of bacterial bronchitis and pneumonia, *I*60–*I*64
small mammals/exotics
bacterial infectious diseases in small mammals, *I*95–*I*106
pharmacokinetics of enrofloxacin in reptiles, *I*110–*I*114
practical antibiotic selection in birds, *I*115–*I*120
use of enrofloxacin in psittacine birds, *I*107–*I*109
urinary tract infections
bacterial prostatitis, canine, *I*73–*I*87
therapy, *I*65–*I*72

G

Gonadectomy, prepubertal, 103–111, 197–201
anesthesia, 106–111
history, 104
postoperative care, 200
pre- and perioperative considerations, 104–106
research studies, 197–198
surgical procedures, 198–200

H

Heartworm, feline, *Alternatives* (December supplement)
Hemangiosarcoma, 622–629, 652
canine, 623–629
feline, 622–623
Highlights and Horizons (see Behavior; Cardiology; Controversies; Dentistry; Emergency; Exotic animal medicine; Flea control; Oncology; Surgery; Technicians)
Hyperadrenocorticism, diagnostic testing for (Continuing Education Series)
hypothalamic-pituitary-adrenal axis, 1154–1156
pathophysiology, 1156–1157, 1159
Hyperthyroidism, feline, 235–244
antithyroid medications, 235–242
β-adrenergic blockers, 243
radioiodine, 242–243
Hyphema, 1064–1069, 1091
blood-ocular barrier, 1064–1065
pathophysiologic approach, 1065–1069

I

Idiopathic lower urinary tract disease, feline, 15–26, 148–154, 587–594, 448, 497–509
amitriptyline, 505–506
analgesics and antiseptics, 499–500
antibacterial agents, 499
antihistamines and mast-cell inhibitors, 506
antiinflammatory agents, 501
autoimmune disease, 150
biologic behavior, 20–22
client education considerations, 507
clinical features, 17–20
crystals, 148–149
cystotomy and biopsy, 594
glycosaminoglycans, 501–505
history and physical examination, 588
incidence, 16
in other species, 24–25
laboratory evaluations, 588–590
leaky urothelium, 150–151
management and prevention of sequelae, 506–507
mast cells, 151
neurogenic inflammation, 151–152
other agents, 506
potential sequelae, 22–24
radiography, 590–592
signalment, 16–17
skeletal and smooth muscle antispasmodics, 500–501
stress, 151
stress reduction, 506
ultrasonography, 592
urethrocystoscopy, 592–594
urine acidifiers, 500
urine toxins, 150
urohydrodistention, 506
uropathogens, 149–150
urothelial debridement, 506
Infections, bacterial skin, feline, 1108–1115, 1161
causes, 1110–1115
diagnostic evaluation, 1109–1110
physical examination, 1109
signalment and history, 1108–1109
Intervertebral disk extrusion, thoracolumbar, 922–951, 1037–1047
anatomy, 925
decision making and prognosis, 928–929
diagnosis, 925–928
medical management, 1038–1039
pathophysiology, 923–924
signalment and clinical signs, 924–925
surgical and other treatments, 1039–1044
Itraconazole, 145–147

M

Microbes, oral, *Veterinary Exchange* (January supplement)
Misoprostol, 66–67
Monitoring, cardiac, event-based, 1025–1033
accessing information, 1027
artifacts, 1027–1028
cases, 1031–1032
owner involvement, 1028
portable recorders, 1025–1027
wireless event-based recorders, 1028–1030
Myasthenia gravis, acquired, in cats, 440–448
materials and methods, 441
results, 441–446

N

Narcolepsy, canine, 641–650
clinical signs, 641–642
diagnosis, 645–646
neurophysiology of sleep, 642–643
pathophysiology, 643–645
treatment, 646–648
Necropsy, 954–960
getting started, 954
procedure, 955–960
sample collection and preparation, 954–955
Neospora caninum, potential for parasite transmission, 517–521

SMALL ANIMAL/EXOTICS SUBJECT INDEX—(continued)

clinical signs, 318–319
diagnosis, 320
importance of the oocyst, 320–321
life cycle, 318
pathogenicity, 319
prevalence, 319
treatment, 320
Neutering (see Gonadectomy)
Nonsteroidal antiinflammatory drugs, renal effects of, 910–919
case examples, 912–914
diagnosis, 915
prognosis and prevention, 915–918
prostaglandin production, 910–911
therapeutic effects, 911
treatment, 915
Nutrition, *1998 Purina Nutrition Forum Proc* (November supplement)
protein, in life stage nutrition
consequences of restricted and high dietary protein, *I25–I31*
effect of moderate protein deficiency on immune function, *I21–I24*
factors influencing lean body mass in aging dogs, *I34–I37*
mythology of protein restriction for dogs with reduced renal function, canine, *I15–I20*
pet food ingredients and ingredient processing affect dietary protein quality, *I38–I43*
research abstracts, *I44–I64*
role in weight management, *I32–I33*
renal function
acid-base and electrolytes, *I1–I4*
dietary lipids, *I11–I14*
dietary protein intake, *I5–I10*
Nutritional products, avian, calculating required volume of, 694–695

O

Oncology, 902–904
Otitis, chronic, canine, 716–728
client education, 726–727
diagnostic tests, 718–720
drug selection, 724–726
ear cleaning, 720–724
normal anatomy and physiology, 717
pathogenesis, 718
pathophysiology of otitis externa and otitis media, 717–718
Oxygen carrying fluids, *Oxygen Carrying Fluids* (August supplement)
applications in anesthesia and surgery, *I2–I5*
treating anticoagulant rodenticide toxicity, *I16–I19*
treating flea anemia, *I11–I15*
treating hemolytic anemia, *I6–I10*
Oxygen therapy, 587–598
administration techniques, 590–592
complications, 596
indications, 589–590
monitoring response, 593–596
pathophysiology of hypoxemia, 589
physiology of oxygen uptake and delivery, 588–589
respiratory physiology, 587–588
Oxygen toxicity, 341–351
antioxidant systems, 345
cellular oxygen injury, 345
neurologic, 348
oxygen metabolism and production of toxic oxygen metabolites, 344–345
pulmonary, 345–348
rational use of oxygen, 341–344
therapy, prevention, and tolerance, 348–349

P

Parasitology (see *Neospora caninum*; *Physaloptera*)
Parenteral nutrition, peripheral, 512–523
administration, 521–522
advantages and disadvantages, 514–515
calculating requirements and formula, 518
complications and monitoring, 522
goals, 513
history, 512–513
indications, 513–514
solution choices, 515–518
sources of compounding, 518–521
Periodontal disease, *Perioceutic Roundtable* (February supplement)
Pharm Profile (see Carprofen; Cisapride; Cyclophosphamide; Enalapril maleate; Etodolac; Famotidine; Itraconazole; Misoprostol; Phenobarbital; Potassium bromide)
Phenobarbital, 905, 987–988
Physaloptera infection, 299–302, 306–314
clinical disease, 300–301
life cycle, 300
pathophysiology, 300
prevalence, 299–300
treatment, 301–302
Potassium bromide, 638–639
Pythons (see Cartilaginous hyperplasia)

R

Rabbits, critically ill, 30–40, 116–125
abdominal discomfort or enlargement, 30–33
anorexia, 33
collapse and seizure, 39
diagnostic procedures, 117–118
diarrhea, 33–36
dyspnea, 36–37
posterior paresis, 37–38
red urine, 37
therapeutic procedures, 118–125
torticollis, 38–39
Raptor medicine, 205–215, 329–338
biology, physiology, and anatomy, 206
bumblefoot, 329–331
fungal infections, 331–332
noninfectious conditions, 208–212
parasitic infections, 334–336
rehabilitation and treatment considerations, 206–208
viral infections, 332–334
Renal disease, chronic, 752–765
applied examples, 762–765
definition of terms, 752–754
stages, 755–762
Respiratory system, avian, 935–943
cycle, 939–942
defense mechanisms of the lower tract, 942–943
lower tract, 937–939
upper tract, 935–937

S

Shampoo, noninsecticidal veterinary, 55–64
antibacterial ingredients, 55–57
antifungal ingredients, 57
antipruritic ingredients, 58
antiseborrheic ingredients, 57
case examples, 58–62
moisturizing ingredients, 57–58
residual-extending ingredients, 58
Spinal trauma, exogenous, 1138–1144
clinical assessment, 1139–1141
corticosteroid therapy, 1141–1142
diagnostic testing, 1141
nonsurgical treatment, 1142–1143
pathophysiology, 1138–1139
Supraventricular tachycardia, 428–439, 843–856
clinical signs, 433
diagnosis, 430–432
hemodynamic consequences, 432–433
identification and treatment of arrhythmias, 844–854
mechanisms of cardiac arrhythmias, 429–430
prognosis, 854–855
supraventricular versus ventricular tachycardia, 432
therapy, 433–438
Surgery, soft tissue, 580–581, 599
Sutures, esophageal, 414–420
anatomy and physiology, 414–415
Dallman's work, 417
methods, 416, 420
reinforcing the suture line, 416
submucosa in the gastrointestinal tract, 416–417
surgical complications, 415–416
Systemic lupus erythematosus, canine, 135–141, 402–410, 421
biologic findings, 137–140
cause, 408–410
clinical aspects, 135–137
diagnosis, 402–403
physiopathology, 408
prognosis, 403
therapy, 403–408

T

Technicians, expanding role, 796–798
Telemedicine, 128–133
Thrombocythemia, essential, 158–167, 218–229
diagnosis, 164–165
hematology and cytology, 220–222
history and physical examination, 218–220
myeloproliferative diseases, 159–161
myeloproliferative versus reactive thrombocytosis, 161–164
recent advances in diagnosis, 226–228
signalment, 218
treatment and prognosis, 222–226
Toxicosis, lead and zinc, from a retained projectile in a bird, 581–583
Tracheostomy, 44–53, 65
anatomy and physiology, 45
indications, 44–45
permanent, 51–53
temporary, 47–51
tracheal wound healing, 45–46
tubes, 46–47
Trauma patients (see Anesthetic agents)
Tumors, bladder, 540–547, 564
biopsy techniques, 542–544
diagnostics, 541–542
history, 541
pathology and biologic behavior, 540–541
signalment, 540
treatment options and prognosis, 544–546

U

Urinary bladder eversion, in rabbit does, 524–528
Urinary tract disease (see Idiopathic)

W

Worms, stomach (see *Physaloptera* infection)

Y

Year 2000 preparation, *Y2K for DVMs* (August supplement)

EQUINE AUTHOR INDEX

B

Baird, A. N., 452
Barton, M. H., 660
Baskett, A., 660
Baxter, G. M., 69
Bentz, B. G., 975
Blikslager, A. T., 548
Brown, M. P., 1082

C

Carter, W. G., 975
Corriher, C. A., 74

D

Dybdal, N. O., 766

F

Fontaine, G. L., 255

G

Gaughan, E. M., *Veterinary Exchange* (January supplement)
Gibbons, D. S., 74

H

Hanson, R. R., 253, 965
Hogan, P. M., *Veterinary Exchange* (January supplement)
Hooper, R. N., 452

L

Levy, M., 766
Little, S. E., 356
Lowder, M. Q., 874, 1150

M

MacKay, R. J., 355
McClure, J., 169
McDonnell, S. M., 265
McFarlane, D., 867
McIlwraith, C. W., 450
Mueller, P. O. E., 660, 874

P

Paradis, M. R., 1147
Parviainen, A. K. J., 74

R

Ragle, C. A., 170
Ralston, S. L., 655
Ramey, D. W., 555
Rhoads, W. S., 770
Rodgerson, D. H., 255

S

Sanderson, S., 662
Sellon, D. C., 74
Sojka, J. E., 766
Steiger, R., 255

T

Taylor, T. S., 452
Tobin, T., 975

W

White II, N. A., 1079

VOLUME 21 EQUINE PAGINATION

Issue	*Pages*	*Issue*	*Pages*
January	**68–88**	**July**	**654–672**
February	**168–184**	**August**	**766–784**
March	**253–280**	**September**	**866–888**
April	**352–368**	**October**	**962–992**
May	**449–464**	**November**	**1078–1096**
June	**548–568**	**December**	**1147–1176**

EQUINE SUBJECT INDEX

A

Alternative medicine (see Magnetic and electromagnetic therapy)
Antibiotics, perioperative, 1082–1085

C

Colloids (see Hetastarch)
Consultant's Corner (see Fractures; Glycosaminoglycans; Inhalant therapies; Isoerythrolysis)
Cushing's disease, 766–769
Cyclooxygenase-2 inhibitors, 548–550

D

Dental disease, periradicular, 874–877
Dentistry (see extraction)

E

Equine Forum (see Cyclooxygenase-2 inhibitors; Tears)
Equine joint disease, *Veterinary Exchange* (January supplement)
  carpus, *I25–I27*
  fetlock and pastern, *I5–I11*
  foot, *I12–I20*
  hock, *I21–I24*
  tendon, treatment of acute injury, *I28–I32*
Equine protozoal myeloencephalitis, 975–981
  antibody and cerebrospinal fluid, 979
  evaluation of response to treatment, 979–980
  laboratory and ancillary diagnostic testing, 977–979
  lameness examination, 977
  physical and neurologic examination, 976–977
Equine Rounds (see Urethral calculus, Urolithiasis)
Extraction, oral, 1150–1157
  cases, 1156
  complications, 1155–1156
  deciduous teeth, 1152–1155
  equipment, 1151–1152
  indications, 1150
  masticatory examination, 1152
  permanent premolars and molars, 1153–1155
  postoperative care, 1155

F

Fractures, limb, stabilizing in foals, 69–71

G

Glycosaminoglycans, oral, 450–451, 457

H

Hetastarch, 867–873, 877
  fluid therapy, 868–869
  kinetics, 869–872
  physiology of body fluid distribution, 867–868
  potential indications, 872–873
Highlights and Horizons (see Surgery)
How I Treat (see Dental; Peritonitis; Weight loss)

I

Inhalant therapies, 355–355
Isoerythrolysis, neonatal, 169, 175

EQUINE SUBJECT INDEX—(continued)

L

Laminitis, treatment with nitroglycerin, 170–174

M

Magnetic and electromagnetic therapy, 555–560
- clinical applications, 558
- electricity and magnetism, 554
- magnetic fields and pain relief, 557–558
- magnetic pad design, 556
- pulsating electromagnetic field therapy, 554–555
- static magnetic field therapy, 555–556
- studies of magnetic fields and blood flow, 556–557

N

Nitroglycerin (see Laminitis)

P

Peritonitis, 965–975
Proximal enteritis, using prokinetic drugs to treat, 1147–1149, 1157

S

Sexual dysfunction, 263–266
Small colon impactions, in adult horses, 770–775
- anatomy, 770
- causes and risk factors, 771
- complications, 774
- diagnosis, 772
- differentials, 771–772
- diseases, 770–771
- prognosis, 774
- treatment, 772–774

Surgery, abdominal, 1079–1081

T

Tapeworms, adult, 356–360
- diagnosis, 357–358
- life cycle and prevalence, 357
- morphology, 356–357
- pathogenesis, 357
- treatment and control, 358–359

Tears, rectal, 452–454
Toxicosis, red maple leaf, 74–80
- case reviews, 78–79
- clinical presentation and pathogenesis, 75–76
- diagnosis, 76–77
- treatment, 78

U

Ultrasonography, transabdominal, equine, 253–262
- anatomy, 255
- diagnosing nongastrointestinal causes of colic, 261
- equipment, 253–254
- gastrointestinal tract examination, 255–261
- general principles, 254–255
- technique, 254

Update on Equine Therapeutics (see Antibiotics; Cushing's disease; Laminitis; Proximal enteritis; Sexual dysfunction)
Urethral calculus, 660–662
Urolithiasis, struvite, 662–665, 667

W

Weight loss, chronic, in geriatric horses, 655–658

FOOD ANIMAL AUTHOR INDEX

A

Allen, M., *S164*
Alsobayil, F. A., *S102*
Amass, S. F., *S60*
Apley, M. D., *S91*, *S250*

B

Barling, K. S., *S137*
Blasi, D. A., *S28*
Brazle, F. K., *S28*
Bryant, L. K., *S86*

C

Chenoweth, P. J., *S98*
Collins, M. T., *S220*
Cooley, J., *S220*
Craig, T. M., *S125*

D

Dee, S., *S92*, *S144*, *S170*, *S258*
De Groot, B. D., *S86*
De Lange, C. F. M., *S48*
Denhart, J. W., *S11*
Dewey, C., *S48*, *S198*
Duhamel, G. E., *S198*

F

Falkner, R., *S242*
Falkner, T. R., *S28*
Field, R. W., *S137*
Fox, M. T., *Veterinary Exchange* (August supplement)

G

Gasbarre, L. C., *Veterinary Exchange* (August supplement)
Gerros, T., *S220*
Gibbs, H., *Veterinary Exchange* (August supplement)

H

Heuser, W., *S196*
Holland, P. S., *S137*
Hutjens, M., *S162*

J

Jarrett, J. A., *S208*
Johnston, T., *S198*

K

Kersting, K. W., *S91*
Kirby, C. J., *S66*
Knittel, J. P., *S55*
Kober, J. A., *S149*
Kuhl, G. L., *S28*

L

Larson, R. L., *S210*, *S235*

M

Mama, K. R., *S102*
Marston, T., *S21*, *S70*
Mathiesen, M. R., *S198*
McClure, J., *S220*
Miller, D. S., *S220*
Murphy, J., *S48*

P

Pierce, V. L., *S210*, *S235*

R

Ridley, R., *S242*
Rogers, G. M., *S66*
Ross, G. S., *S86*

S

Sanderson, M. W., *S98*
Sarr, R., *S11*
Scharko, P., *S119*
Schultz, L. G., *S86*
Selk, G., *S179*
Smart, N., *S198*
Smith, B. B., *S220*
Stokka, G. L., *S28*, *S242*
Stromberg, B. E., *Veterinary Exchange* (August supplement)
Szkotnicki, B., *S48*

T

Thacker, B. J., *S149*
Thurmon, J. C., *S11*
Townsend, L., *S119*

V

VanBoening, J. D., *S242*
Van Metre, D., *S242*
Vestweber, J. G., *S54*

W

Walter, D., *S198*
White, C., *S137*
Wikse, S. E., *S137*

VOLUME 21 FOOD ANIMAL PAGINATION

Issue	*Pages*	*Issue*	*Pages*
January	S1–S40	August	S153–S192
February	S41–S80	September	S193–S232
March	S81–S112	October	S233–S248
April	S113–S152	November	S249–S264

FOOD ANIMAL SUBJECT INDEX

A

Anthelmintic dilemma, S125–S135, S143
Ask the Expert (see *Cryptosporidium* infection)

B

Beef Production Management (see Lice infestation; Response trials)
Bovine Production Management (see Anthelmintic dilemma; Implants)
Bovine somatotropin, S162–S163, S176–S177
Buller syndrome, in feedlot steers, S250–S256, S264
  attempted therapies, S255
  management, S255–S256
  proposed causes, S251–S255

C

Camels, dromedary, anesthetic management of, S102–S111
  induction agents, S106–S108
  intubation, S109
  monitoring anesthetic depth, S109–S110
  preanesthetic medication, S105–S106
  preanesthetic preparation, S102–S105
  recovery, S110
  regional anesthesia, S109
Cow/Calf Herd Investigation (see Sicklepod toxicity)
Cryptosporidiosis, S242–S246
  control, S244–S245
  diagnosis, S244
  epidemiology, S242–S243
  prevalence and clinical presentation, S243–S244
  treatment, S244
Cryptosporidium infection, in calves, antimicrobial therapy for, S91, S97

D

Dairy Nutrition Management (see Bovine somatotropin; Fiber requirements), S208–S209, S232

E

Economics, agricultural, S210–S219, S235–S241, S247
  efficiency and profitability, S211–S213, S235–S236
  marketing alternatives, S236–S240
  partial budgeting, S210–S211, S213–S217
Erysipelas, S60–S63

F

Feed intake and growth curves, establishing for individual growing-finishing pig units, S48–S51, S80
Feedlot Nutrition Management (see Stocker cattle; Supplementation)
Fiber requirements, in dairy cattle, S164–S169

G

Gilt pool management, S196–S197, S232

H

Highlights and Horizons (see Dairy Nutrition Management)

I

Implants, for suckling steer and heifer calves, S179–S192

L

Lawsonia intracellularis (see Porcine proliferative enteropathy)
Lice infestation, in beef cattle, S119–S123
Llamas and alpacas, paratuberculosis in, S220–S229
  clinical signs and pathology, S221–S224
  diagnosis, S224–S226
  management in South American camelids, S226–S227

N

Nursery pig health and performance (Continuing Education Series)
  Bordetella bronchiseptica, S170–S171
  multisystem interaction, S145
  Mycoplasma hyopneumoniae, S173–S174
  neonatal immune response, S144–S145
  nursery considerations, S95–S96
  nutritional modifications, S95
  other factors, S145–S146
  Pasteurella multocida, S171–S173
  porcine respiratory coronavirus, S262–S263
  postweaning digestive system changes, S92–S95
  pseudorabies virus, S258–S261
  reducing weaning stress, S146
  swine influenza virus, S261–S262

O

Otitis media/interna, in cattle, S54–S58
  herd reports, S54–S55
  individual reports, S55–S56

P

Parasites, internal, impact on calf performance, *Veterinary Exchange* (August supplement)
Paratuberculosis (see Llamas)
Penile deviation, using to prepare teaser bulls, S86–S89, S112
  postoperative follow-up, S88–S89
  technique, S87–S88
Piglet performance, day 1 versus day 2 processing, S149–S151
Porcine colonic spirochetosis, S198–S207, S230–S231
  causative agent, S199
  clinical signs, S200
  control, S203–S205
  diagnosis, S202–S203
  dietary factors, S202
  differential diagnosis, S203
  epidemiology, S199–S200
  experimental studies, S202
  pathogenesis, S201–S202
  pathology, S200–S201
Porcine proliferative enteropathy, S53–S59, S77–S78
  antibiotic treatment and prevention, S57–S58
  cause, S54–S55
  clinical signs, S53
  diagnosis, S55–S57
  economics, S57
  epidemiology, S57
  isolation and growth of *Lawsonia intracellularis*, S55
  lesions, S53–S54
  transmission, S55

R

Reproduction, bovine (see *Ureaplasma diversum*)
Response trials, clinical, in beef cattle practice, S137–S143

S

Sedatives, S11–S20
  tolazoline, S17–S18
  xylazine, S11–S16
Sicklepod toxicity, S66–S69, S79
Stocker cattle, nutrition and management, S28–S33, S40
Supplementation, trace mineral, in beef cattle, S21–S27, S70–S77
Swine Herd Investigation (see Piglet performance)
Swine Nutrition Management (see Feed intake)
Swine Production Management (see Erysipelas; Gilt Pool)

T

Teaser-bull preparation (see Penile deviation)

U

Ureaplasma diversum, role in bovine reproduction, S98–S101, S111
  clinical syndromes in bulls, S100
  clinical syndromes in cows, S98–S100
  prevention and control, S100
  sample collection and submission, S101